Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SacI-81
- Development stage
- Preclinical
- Lead developer
- Corellia AI
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SacI-81 is an antibody-drug conjugate (ADC) developed by Corellia AI, utilizing its proprietary Coromip technology to deliver a potent small molecule payload to TROP2-expressing cancer cells. The ADC consists of a monoclonal antibody targeting Trophoblast cell-surface antigen 2 (TROP2) conjugated to omipalisib (compound '81'), a dual inhibitor of Phosphatidylinositol 3-kinase (PI3K) and Mammalian target of rapamycin (mTOR). By specifically binding to TROP2, which is overexpressed in various solid tumors, SacI-81 facilitates the intracellular delivery of omipalisib, thereby inhibiting the PI3K/AKT/mTOR signaling pathway and inducing tumor cell death. SacI-81 is currently in preclinical development for multiple indications, including ER+/HER2- breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, and EGFR- or KRAS-mutant non-small cell lung cancer (NSCLC).
- Other names
- SacI-81-Corellia AI-TROP2-PI3K/mTOR (Omipalisib warhead)-ADC
02
Targets
PI3K (Phosphoinositide-3-kinase regulatory subunit 6)TACSTD2 (Tumor-associated calcium signal transducer 2)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on SacI-81.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SacI-81.